Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BVS NASDAQ:INMD NASDAQ:RXST NASDAQ:SIBN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$9.69+4.3%$9.56$5.81▼$11.25$810.25M0.67448,625 shs225,681 shsINMDInMode$15.06+12.8%$13.88$12.72▼$16.74$868.02M1.94975,178 shs2.38 million shsRXSTRxSight$5.36+2.6%$5.94$4.48▼$13.96$221.68M1.14878,858 shs247,427 shsSIBNSiBone$16.60+4.0%$14.27$11.48▼$21.89$736.39M0.7627,420 shs179,087 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus+5.69%+6.54%+0.11%+1.42%+928,999,900.00%INMDInMode+1.06%-1.04%-2.84%-2.91%-1.04%RXSTRxSight+5.24%+11.54%-14.29%-20.79%-61.45%SIBNSiBone+0.82%+3.50%+8.65%+23.55%-3.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$9.69+4.3%$9.56$5.81▼$11.25$810.25M0.67448,625 shs225,681 shsINMDInMode$15.06+12.8%$13.88$12.72▼$16.74$868.02M1.94975,178 shs2.38 million shsRXSTRxSight$5.36+2.6%$5.94$4.48▼$13.96$221.68M1.14878,858 shs247,427 shsSIBNSiBone$16.60+4.0%$14.27$11.48▼$21.89$736.39M0.7627,420 shs179,087 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus+5.69%+6.54%+0.11%+1.42%+928,999,900.00%INMDInMode+1.06%-1.04%-2.84%-2.91%-1.04%RXSTRxSight+5.24%+11.54%-14.29%-20.79%-61.45%SIBNSiBone+0.82%+3.50%+8.65%+23.55%-3.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 3.00Buy$14.2046.54% UpsideINMDInMode 2.00Hold$16.006.28% UpsideRXSTRxSight 1.93Reduce$9.4476.37% UpsideSIBNSiBone 2.71Moderate Buy$23.0038.60% UpsideCurrent Analyst Ratings BreakdownLatest RXST, INMD, BVS, and SIBN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026BVSBioventus Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.006/11/2026RXSTRxSight Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/2/2026BVSBioventus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/22/2026RXSTRxSight Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026BVSBioventus Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$14.005/12/2026SIBNSiBone TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.00 ➝ $18.005/12/2026SIBNSiBone Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00 ➝ $18.005/7/2026RXSTRxSight Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026INMDInMode BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$21.00 ➝ $19.005/7/2026INMDInMode Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$17.00 ➝ $14.005/7/2026RXSTRxSight Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$11.00 ➝ $9.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$568.09M1.42$1.41 per share6.89$2.76 per share3.51INMDInMode$374.64M2.31$1.70 per share8.85$10.78 per share1.40RXSTRxSight$127.48M1.74N/AN/A$6.70 per share0.80SIBNSiBone$200.93M3.66N/AN/A$4.09 per share4.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus$22.73M$0.4123.6611.011.134.94%29.97%9.52%N/AINMDInMode$93.83M$1.3611.10N/AN/A23.27%13.47%11.95%7/23/2026 (Estimated)RXSTRxSight-$38.94M-$1.13N/AN/AN/A-36.58%-17.01%-15.12%8/6/2026 (Estimated)SIBNSiBone-$18.90M-$0.39N/AN/AN/A-8.10%-9.56%-7.06%8/3/2026 (Estimated)Latest RXST, INMD, BVS, and SIBN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026SIBNSiBone-$0.17-$0.10+$0.07-$0.10$51.16 million$52.59 million5/6/2026Q1 2026BVSBioventus$0.09$0.15+$0.06$0.04N/A$132.09 million5/6/2026Q1 2026INMDInMode$0.2978$0.25-$0.0478$0.18$79.84 million$82.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/AINMDInModeN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ASIBNSiBoneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.081.691.13INMDInModeN/A8.807.88RXSTRxSightN/A10.208.93SIBNSiBone0.209.998.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%INMDInMode68.04%RXSTRxSight78.78%SIBNSiBone98.11%Insider OwnershipCompanyInsider OwnershipBVSBioventus33.00%INMDInMode6.92%RXSTRxSight10.05%SIBNSiBone3.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20083.54 million55.97 millionN/AINMDInMode48057.48 million58.98 millionOptionableRXSTRxSight22041.40 million37.24 millionOptionableSIBNSiBone35044.35 million42.62 millionOptionableRXST, INMD, BVS, and SIBN HeadlinesRecent News About These CompaniesSiBone (NASDAQ:SIBN) Given Consensus Rating of "Moderate Buy" by AnalystsJune 20, 2026 | americanbankingnews.comJeffrey Dunn Sells 3,575 Shares of SiBone (NASDAQ:SIBN) StockJune 9, 2026 | insidertrades.comSiBone $SIBN Shares Purchased by Northwestern Mutual Wealth Management Co.June 5, 2026 | marketbeat.comSI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026June 4, 2026 | globenewswire.comBears are Losing Control Over Si-Bone (SIBN), Here's Why It's a 'Buy' NowJune 3, 2026 | zacks.comSiBone (NASDAQ:SIBN) Director Timothy Davis, Jr. Sells 3,500 SharesJune 2, 2026 | insidertrades.comWall Street Analysts Predict a 71.13% Upside in Si-Bone (SIBN): Here's What You Should KnowJune 1, 2026 | zacks.comGazprom Neft says Q1 profit down 3.5% y/yMay 29, 2026 | reuters.comUBS Group AG Raises Stake in SiBone $SIBNMay 29, 2026 | marketbeat.comSiBone (NASDAQ:SIBN) SVP Sells 3,726 SharesMay 21, 2026 | insidertrades.comAnshul Maheshwari, CFO of SI-BONE, sells $60k in SIBN stockMay 15, 2026 | investing.comHow Much Upside is Left in Si-Bone (SIBN)? Wall Street Analysts Think 65.27%May 15, 2026 | zacks.comSI-BONE targets $230M-$233M 2026 revenue while CMS proposes new DRGs that could add up to $50,000 per Granite procedureMay 14, 2026 | seekingalpha.comSI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comSI-BONE, Inc. (SIBN) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comSI-BONE, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 12, 2026 | seekingalpha.comSI-BONE, Inc. (NASDAQ:SIBN) Q1 2026 Earnings Call TranscriptMay 12, 2026 | insidermonkey.comSi-Bone (SIBN) Reports Q1 Loss, Tops Revenue EstimatesMay 11, 2026 | zacks.comSI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 GuidanceMay 11, 2026 | globenewswire.comSI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026April 30, 2026 | globenewswire.comSI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026April 20, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRXST, INMD, BVS, and SIBN Company DescriptionsBioventus NASDAQ:BVS$9.69 +0.40 (+4.31%) As of 12:47 PM Eastern This is a fair market value price provided by Massive. Learn more.Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.InMode NASDAQ:INMD$15.06 +1.71 (+12.77%) As of 12:46 PM Eastern This is a fair market value price provided by Massive. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.RxSight NASDAQ:RXST$5.36 +0.14 (+2.59%) As of 12:46 PM Eastern This is a fair market value price provided by Massive. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.SiBone NASDAQ:SIBN$16.60 +0.65 (+4.04%) As of 12:47 PM Eastern This is a fair market value price provided by Massive. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning Why nVent Could Be a Long-Term AI Infrastructure Winner These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Chevron’s Microsoft Deal Turns Natural Gas Into an AI Trade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
